دورية أكاديمية
أعرض في EDS

Evidence for deleterious effects of immunological history in SARS-CoV-2.

التفاصيل البيبلوغرافية
العنوان: Evidence for deleterious effects of immunological history in SARS-CoV-2.
المؤلفون: Sen SR; Department of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, CA, United States of America., Sanders EC; Department of Chemistry, University of California, Irvine, Irvine, CA, United States of America., Santos AM; Department of Chemistry, University of California, Irvine, Irvine, CA, United States of America., Bhuvan K; Department of Chemistry, University of California, Irvine, Irvine, CA, United States of America., Tang DY; Department of Chemistry, University of California, Irvine, Irvine, CA, United States of America., Gelston AA; Department of Chemistry, University of California, Irvine, Irvine, CA, United States of America., Miller BM; Department of Chemistry, University of California, Irvine, Irvine, CA, United States of America., Ricks-Oddie JL; Center for Statistical Consulting, Department of Statistics, University of California, Irvine, Irvine CA, United States of America.; Biostatics, Epidemiology and Research Design Unit, Institute for Clinical and Translational Sciences, University of California, Irvine, Irvine, CA, United States of America., Weiss GA; Department of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, CA, United States of America.; Department of Chemistry, University of California, Irvine, Irvine, CA, United States of America.; Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, United States of America.
المصدر: PloS one [PLoS One] 2022 Aug 24; Vol. 17 (8), pp. e0272163. Date of Electronic Publication: 2022 Aug 24 (Print Publication: 2022).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: COVID-19* , Influenza Vaccines* , Influenza, Human*/prevention & control, Antibodies, Viral ; Epitopes ; Humans ; Influenza A Virus, H3N2 Subtype ; Neuraminidase ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus
مستخلص: A previous report demonstrated the strong association between the presence of antibodies binding to an epitope region from SARS-CoV-2 nucleocapsid, termed Ep9, and COVID-19 disease severity. Patients with anti-Ep9 antibodies (Abs) had hallmarks of antigenic interference (AIN), including early IgG upregulation and cytokine-associated injury. Thus, the immunological memory of a prior infection was hypothesized to drive formation of suboptimal anti-Ep9 Abs in severe COVID-19 infections. This study identifies a putative primary antigen capable of stimulating production of cross-reactive, anti-Ep9 Abs. Binding assays with patient blood samples directly show cross-reactivity between Abs binding to Ep9 and only one bioinformatics-derived, homologous putative antigen, a sequence derived from the neuraminidase protein of H3N2 influenza A virus. This cross-reactive binding is highly influenza strain specific and sensitive to even single amino acid changes in epitope sequence. The neuraminidase protein is not present in the influenza vaccine, and the anti-Ep9 Abs likely resulted from the widespread influenza infection in 2014. Therefore, AIN from a previous infection could underlie some cases of COVID-19 disease severity.
Competing Interests: The authors have declared that no competing interests exist.
References: PLoS Comput Biol. 2021 Jan 28;17(1):e1008667. (PMID: 33507980)
Science. 2020 Dec 11;370(6522):1339-1343. (PMID: 33159009)
Sci Rep. 2015 Oct 16;5:15279. (PMID: 26472175)
J Infect Dis. 2017 Jun 15;215(12):1782-1788. (PMID: 28398521)
Sci Rep. 2017 Sep 5;7(1):10480. (PMID: 28874689)
Malawi Med J. 2012 Sep;24(3):69-71. (PMID: 23638278)
PLoS Comput Biol. 2012;8(12):e1002829. (PMID: 23300419)
mSphere. 2021 Mar 10;6(2):. (PMID: 33692194)
Nucleic Acids Res. 2017 Jul 3;45(W1):W24-W29. (PMID: 28472356)
Bioinformatics. 2020 Mar 1;36(6):1765-1771. (PMID: 31697312)
Nucleic Acids Res. 1997 Sep 1;25(17):3389-402. (PMID: 9254694)
Monoclon Antib Immunodiagn Immunother. 2020 Aug;39(4):107-111. (PMID: 32762609)
Protein Sci. 2006 Mar;15(3):478-86. (PMID: 16452625)
Electrophoresis. 2009 Jun;30 Suppl 1:S162-73. (PMID: 19517507)
Science. 2020 Nov 27;370(6520):. (PMID: 32994364)
Front Immunol. 2020 Jun 05;11:1120. (PMID: 32582200)
Nucleic Acids Res. 2019 Jul 2;47(W1):W256-W259. (PMID: 30931475)
Int J Biol Sci. 2022 Sep 1;18(15):5591-5606. (PMID: 36263161)
mSphere. 2021 Apr 28;6(2):. (PMID: 33910993)
Front Immunol. 2022 Apr 13;13:867716. (PMID: 35493512)
Life (Basel). 2021 Apr 01;11(4):. (PMID: 33915711)
J Infect Dis. 2016 Oct 1;214(7):1010-9. (PMID: 27190176)
Nucleic Acids Res. 2017 Jan 4;45(D1):D313-D319. (PMID: 27899672)
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303. (PMID: 29788355)
Viruses. 2020 Jul 07;12(7):. (PMID: 32646015)
Nucleic Acids Res. 2014 Jan;42(Database issue):D297-303. (PMID: 24319143)
J Biotechnol. 2020 Jun 10;316:27-34. (PMID: 32302655)
Cell. 2021 Apr 1;184(7):1858-1864.e10. (PMID: 33631096)
Viruses. 2020 May 30;12(6):. (PMID: 32486222)
Sci Adv. 2021 Mar 5;7(10):. (PMID: 33674317)
معلومات مُعتمدة: R01 HG009188 United States HG NHGRI NIH HHS; T34 GM069337 United States GM NIGMS NIH HHS; UL1 TR001414 United States TR NCATS NIH HHS
المشرفين على المادة: 0 (Antibodies, Viral)
0 (Epitopes)
0 (Influenza Vaccines)
0 (Spike Glycoprotein, Coronavirus)
0 (spike protein, SARS-CoV-2)
EC 3.2.1.18 (Neuraminidase)
تواريخ الأحداث: Date Created: 20220824 Date Completed: 20220826 Latest Revision: 20230917
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9401162
DOI: 10.1371/journal.pone.0272163
PMID: 36001626
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0272163